bi 836858
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 13, 2012 (NCT01690624)
Timeline
Indications
Mechanism of action
- Myeloid cell surface antigen CD33INHIBITOR
CD33 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSJA7I0QFJ17 ↗
Also known as
- bi 836858
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03207191 | Phase 1 | Nov 30, 2016 | Boehringer Ingelheim, Philogen S.p.A. |
| NCT03013998 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Beat AML |
| NCT02632721 | Phase 2 | Jun 16, 2016 | Boehringer Ingelheim |
| NCT02240706 | Phase 2 | Jan 22, 2015 | Boehringer Ingelheim |
| NCT01690624 | Phase 1 | Sep 13, 2012 | Boehringer Ingelheim |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 4 | 3 | 2 | 2012 |
| Beat AML | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Philogen S.p.A. | For profit | 1 | 1 | 1 | 2016 |
3 organizations
Page 1 / 1